Patents by Inventor Sjoerd Henricus Van Der Burg

Sjoerd Henricus Van Der Burg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES
    Publication number: 20230256075
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: September 19, 2022
    Publication date: August 17, 2023
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus VAN DER BURG, Gemma G. KENTER, Cornelis Johannes Maria MELIEF
  • TEIPP PEPTIDE VARIANT AND USES THEREOF
    Publication number: 20230035037
    Abstract: Novel nucleic acid sequences, vectors, cells, binding agents, peptides and pharmaceutical compositions are provided that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 2, 2023
    Inventors: Thorbald VAN HALL, Sjoerd Henricus VAN DER BURG, Koen MARJIT
  • HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
    Patent number: 11458198
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: October 4, 2022
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES
    Publication number: 20200289640
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 17, 2020
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
    Patent number: 10688173
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 23, 2020
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES
    Publication number: 20190184002
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 20, 2019
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus VAN DER BURG, Gemma G. KENTER, Cornelis Johannes Maria MELIEF
  • HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
    Patent number: 10258684
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: April 16, 2019
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES
    Publication number: 20170348410
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: August 16, 2017
    Publication date: December 7, 2017
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus VAN DER BURG, Gemma G. KENTER, Cornelis Johannes Maria MELIEF
  • HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
    Patent number: 9764023
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: September 19, 2017
    Assignee: Academish Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Melief
  • INTRADERMAL HPV PEPTIDE VACCINATION
    Publication number: 20170143818
    Abstract: The invention relates to the use of a peptide derived from HPV-E2, -E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for interdermal administration.
    Type: Application
    Filed: December 16, 2016
    Publication date: May 25, 2017
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus VAN DER BURG, Gemma G. KENTER, Cornelis Johannes Maria MELIEF
  • Intradermal HPV peptide vaccination
    Patent number: 9562075
    Abstract: The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: February 7, 2017
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES
    Publication number: 20150056234
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: August 6, 2014
    Publication date: February 26, 2015
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Sjoerd Henricus VAN DER BURG, Gemma G. KENTER, Cornelis Johannes MELIEF
  • p53 Peptide Vaccine
    Publication number: 20150010586
    Abstract: The invention relates to a peptide derived from p53 that could be used as a vaccine against cancer.
    Type: Application
    Filed: March 4, 2014
    Publication date: January 8, 2015
    Inventors: Sjoerd Henricus van der BURG, Cornelis Johannes M. MELIEF, Rienk OFFRINGA
  • P53 peptide vaccine
    Patent number: 8663646
    Abstract: The invention relates to a peptide derived from p53 that could be used as a vaccine against cancer.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: March 4, 2014
    Assignee: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Sjoerd Henricus van der Burg, Rienk Offringa, Cornelis Johannes Maria Melief, Gemma G. Kenter
  • P53 peptide vaccine
    Publication number: 20100210529
    Abstract: The invention relates to a peptide derived from p53 that could be used as a vaccine against cancer.
    Type: Application
    Filed: December 3, 2009
    Publication date: August 19, 2010
    Applicant: Acadamisch Ziekenhuis Leiden h.o.d.n LUMC
    Inventors: Sjoerd Henricus van der Burg, Rienk Offringa, Cornelis Johannes Maria Melief, Gemma G. Kenter
  • INTRADERMAL HPV PEPTIDE VACCINATION
    Publication number: 20100196353
    Abstract: The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration.
    Type: Application
    Filed: May 27, 2008
    Publication date: August 5, 2010
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N.
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
    Publication number: 20100189742
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: February 16, 2010
    Publication date: July 29, 2010
    Applicant: Academisch Ziekenhuis Leiden h.o.d.n LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • Synthetic Protein as Tumor-Specific Vaccine
    Publication number: 20090028874
    Abstract: The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a fully synthetic vaccine. The invention is illustrated mainly by using HPV protein directed immunity as a model.
    Type: Application
    Filed: December 24, 2003
    Publication date: January 29, 2009
    Applicant: LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Sjoerd Henricus Van Der Burg, Jan Wouter Drijfhout